Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials

Xenon Pharmaceuticals Inc.

2023-Q1 EPS reported -$0.63

Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.
R&D expenses $39.5M, up $20.2M YoY driven by XEN1101 Phase 3 studies and X-NOVA MDD trial.
Cash $687.3M as of March 31, 2023; expects to fund operations into 2026.
XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) recruiting; pediatric expansion to include children ≥12.
Phase 2 X-NOVA MDD study last patient screening expected June 2023; topline data Q4 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

the Company’s financial results for the three months ended March 31, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.